Is There Value to the Use of Corticosteroids in Women with Short Cervix Who Are Asymptomatic?
BACKGROUND AND PURPOSE:
ACOG recommends antenatal corticosteroids between 24 and 34 weeks for women “at risk” for delivery within 7 days
While there is demonstrated benefit to antenatal corticosteroids, there are also potential harms, especially with multiple doses
A short cervix is a risk factor for preterm birth
Richards et al. (Amer J Perinatol, 2017) sought to evaluate the number of asymptomatic women with a short cervix who would benefit from antenatal corticosteroids based on the recommended treatment window
The authors also assessed whether waiting until patients were asymptomatic would allow for a full course prior to delivery
Retrospective chart review
Inclusion: Patients with short cervix between 23w0d and 33w6d who had a cervical length < 2.5 cm and were asymptomatic
Antenatal corticosteroids were administered at the discretion of the MFM
367 asymptomatic patients were included, with only two delivering within 7 days from the time a short cervix was identified
2/3 of asymptomatic patients with a short cervix received antenatal corticosteroids based on additional risk factors such as prior history of preterm birth
Number needed to treat (NNT): 184 asymptomatic patients would need to be treated at the time a short cervix is identified for one patient to benefit
If a more stringent cervical length criteria was used, e.g., 2.0 cm cutoff, NNT would be 130
6% of patients delivered within 48 hours after onset of symptoms with a median time to delivery of 4 hours
Waiting for symptoms would not have provided benefit due to short interval until delivery
The authors conclude that unless future studies demonstrate neonatal benefit of administration, antenatal corticosteroids should not be given to women solely because of shortened cervix
Please login to access ObGFirst and the T2 US Atlas
Media - Internet
Computer System Requirements
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan